Physician profile
Mark D Callender
NPI 1942406616
$3,898.27
in general payments reported to CMS, 2019-2025
22 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.61 · 2022: $159 · 2023: $1,003 · 2024: $1,020 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192 · Education: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.16 |
| Education | $453.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $633.63 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $629.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $420.67 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $413.86 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $285.32 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $271.84 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $228.31 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $197.69 | 2022-2025 | |
| Amgen INC. | $149.53 | 2023-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $92.24 | 2023-2024 | Ycanth |
| Pfizer INC. | $88.66 | 2021-2025 | |
| Incyte Corporation | $82.32 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.01 | 2023-2024 | Duobrii, Siliq, Jublia |
| Novartis Pharmaceuticals Corporation | $45.36 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $43.41 | 2025 | Clindacin Etz |
| Almirall LLC | $41.02 | 2025 | Klisyri |
| Lnhc, INC | $39.46 | 2025 | Zelsuvmi |
| Organon LLC | $30.93 | 2025 | Vtama |
| Lilly USA, LLC | $27.76 | 2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $18.85 | 2023 | Winlevi, Absorica Ld |
| Organogenesis INC. | $17.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Callender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.